TY - JOUR
T1 - Angiotensin-converting enzyme inhibitors in patients with Alport syndrome
T2 - can all patients benefit?
AU - Rheault, Michelle N.
N1 - Publisher Copyright:
© 2020 International Society of Nephrology
PY - 2020/12
Y1 - 2020/12
N2 - Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are prescribed to slow the progression of kidney disease in patients with Alport syndrome. In a recent publication by Yamamura et al. the authors showed an association of ACEi or ARB treatment with delay in ESKD, even for those patients with severe, truncating mutations. Despite these encouraging findings, there remain a number of clinical questions about the use of ACEi and ARBs in Alport syndrome.
AB - Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are prescribed to slow the progression of kidney disease in patients with Alport syndrome. In a recent publication by Yamamura et al. the authors showed an association of ACEi or ARB treatment with delay in ESKD, even for those patients with severe, truncating mutations. Despite these encouraging findings, there remain a number of clinical questions about the use of ACEi and ARBs in Alport syndrome.
UR - http://www.scopus.com/inward/record.url?scp=85096877773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096877773&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2020.07.011
DO - 10.1016/j.kint.2020.07.011
M3 - Comment/debate
C2 - 33276866
AN - SCOPUS:85096877773
SN - 0085-2538
VL - 98
SP - 1400
EP - 1402
JO - Kidney international
JF - Kidney international
IS - 6
ER -